Navigation Links
Phase III Clinical Trial with 4-Month Long-Acting Formulation of,Triptorelin: Ipsen Decides Not to Perform Further Administration

art of the SBF 250 index. For more information on Ipsen, visit our website at www.ipsen.com.

Forward-looking statements

The forward-looking statements and targets contained herein are based on Ipsen's management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Moreover, the Research and Development process involves several stages at each of which there is a substantial risk that the Group will fail to achieve its objectives and be forced to abandon its efforts in respect of a product in which it has invested significant sums. Therefore, the Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its information documents filed with the French Autorite des Marches Financiers.

Contact

Ipsen
Didier Véron, Director,
Public Affairs and Corporate Communications
Tel.: +33 (0)1 44 30 42 38 - Fax: +33 (0)1 44 30 42 04
E-mail : didier.veron@ipsen.com
or
David Schilansky, Investor Relations Officer
Tel.: +33 (0)1 44 30 43 31 - Fax: +33 (0)1 44 30 43 21
E-mail: david.schilansky@ipsen.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:7/11/2014)... 2014  Veran Medical Technologies, a U.S. ... positive, cost-effective final results for the initial ... SPiNPerc endobronchial percutaneous biopsy study results support ... biopsy when a traditional bronchoscopic method is ... positive financial outcomes when more can be ...
(Date:7/10/2014)... 2014  Major advances in radiation therapy and ... highlighted in a three-day Oncology Summit taking place ... 2014.  Renowned national and international cancer experts from seven ... exchange knowledge on modern technologies making treatment for ... The Summit will address a wide ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... , , CLEVELAND, Dec. 15 At today,s ... (NYSE: LZ ), the board declared a regular quarterly ... holders of record at the close of business on February 10, ... Corporation (NYSE: LZ ) is an innovative specialty chemical ...
... , BATESVILLE, Ind., Dec. 15 Today, Hill-Rom Holdings, Inc. ... on significant strategic and financial initiatives at its Investor Conference ... Peter H. Soderberg, president and CEO of Hill-Rom, and will ... multi-year strategic initiatives Business unit, research and development and ...
Cached Medicine Technology:Lubrizol Declares Dividend 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7
(Date:7/14/2014)... The Cabin Chiang Mai, Asia’s leading inpatient addiction treatment ... – a free comprehensive aftercare service for clients ... wherever they live in the world. , The Cabin ... them maintain their recovery after successfully completing primary treatment ... programme. As a chronic disease, addicts in recovery are ...
(Date:7/14/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on Hospira Lactated Ringer’s and 5% ... 11, that one lot of Lactated Ringers and 5% ... Inc., is recalled due to mold contamination. The specific ... of fluid and electrolytes, with or without minimal carbohydrate ...
(Date:7/14/2014)... According to the Blood Pressure Solution book review recently ... a series of new information on high blood pressure ... can help readers understand more about blood pressure. The book ... methods to control hypertension naturally. , Blood ... penned by Ken Burge, a medical researcher and health consultant. ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 According to the Boost ... helpful book for women who want to learn how to increase ... This book consists of 7 chapters including:, , ... Grow? , Chapter 2 – How Natural Breast Enlargement ... Your Breasts Look Bigger , Chapter 4 – The ...
(Date:7/14/2014)... "Medical devices, tests, and treatments are critical ... is a star when it comes to innovations in ... working on amazing products and ideas that are our ... to Dale Kaye CEO of the Innovation Tri-Valley ... brilliant minds and businesses that are leading society into ...
Breaking Medicine News(10 mins):Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 2Health News:Hospira Lactated Ringer’s and 5% Dextrose Injection Recalled: AttorneyOne Monitor and Keep Consumers Informed 3Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4
... ... material testing, announced that via findings from their 3rd quarter "Packaging Quizzler" nearly half ... humidity should mimic the equivalent water content. , ... Minneapolis, MN (PRWEB) October 19, 2009 -- DDL, leader ...
... of thiopurines bears further study, researchers say , MONDAY, ... drugs to treat inflammatory bowel disease (IBD) increases the ... a new study. , IBD includes Crohn,s disease and ... immune system in order to maintain remission in IBD ...
... N.J. Oct. 19 America,s Toughest Trainer and Health ... is designed specifically for on-the-go fitness! Majesco Entertainment Company ... games for the mass market, and Interactive Game Group, ... for Nintendo DS(TM) will be available at retailers ...
... has been awarded special federal funding to support the ... Medicare Quality Improvement Organization (QIO) for the state of ... in a variety of settings. QIOs operate in all ... federal Centers for Medicare & Medicaid Services (CMS). , ...
... 19 As flu season is fast reaching its ... hold among workers, with more than 70 percent saying ... Now(SM) survey released today from ComPsych Corporation. Almost half ... and the touching of workplace surfaces in order to ...
... suggests a connection with lupus, rheumatoid arthritis , ... a link between women,s exposure to household insecticides -- ... disorders rheumatoid arthritis and lupus. , The scientist did ... and the illnesses, and it,s possible that the women ...
Cached Medicine News:Health News:DDL's 'Packaging Quizzler' Tests Medical Device Packaging Professionals' Knowledge on Appropriate Humidity Used for Accelerated Aging 2Health News:Drugs for Inflammatory Bowel Might Increase Cancer Risk 2Health News:Majesco Entertainment and Interactive Game Group Release 'Jillian Michaels Fitness Ultimatum 2010' For Nintendo DS(TM) 2Health News:Majesco Entertainment and Interactive Game Group Release 'Jillian Michaels Fitness Ultimatum 2010' For Nintendo DS(TM) 3Health News:IPRO Wins Federal Contract to Support Hospice Oversight 2Health News:New Flu Poll: Employees Avoid Each Other to Prevent Flu, Yet Almost One-Third Not Changing Behavior 2Health News:Household Insecticides May Be Linked to Autoimmune Diseases 2Health News:Household Insecticides May Be Linked to Autoimmune Diseases 3
... This microtome is the most convenient ... research and in industrial laboratories. Specimen rise ... setting from 0.5 to 12 microns in ... all MNL Freezing Stages.,Other Associated Products, ...
... The Starter Package is a ... laboratory. The package includes the Vibratome ... blocks, v-block adapter, specimen mounts w/1/2" ... for ease in all of your ...
... is a solid solution for ... package includes the Vibratome Plus, ... blocks, v-block adapter, specimen mounts ... stage assembly for ease in ...
... The Vibratome 1500 Sectioning System provides a ... animal, or plant tissues. The 1500 ... sectioning without freezing or embedding. The ... the destruction of enzyme activities, and other ...
Medicine Products: